Inimmune Announces First Subject Dosed in First-in-Human Phase 1 Clinical Trial of its novel intranasal TLR4 agonist, INI-2004, for the Treatment of Allergic Rhinitis and FDA Clearance of IND application for INI-2004 August 8, 2023August 8, 2023 Montana Bioscience Enterprises in the News 0 Comments by Suzanne Lagoni Milestone marks transition of Inimmune Corporation to a clinical-stage company. Facebook Twitter Pinterest Previous Post Next Post